Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations in Massachusetts

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medical risks and pharmaceutical benefits. This legacy framework emphasizes broad awareness of how medications interact with biological systems, often focusing on common side effects and population-level outcomes. Within this context, bisphosphonates like Fosamax were widely prescribed for bone density management, with their benefits communicated through standard health education channels. However, as real-world data accumulated, a more specific concern emerged: the potential for prolonged bisphosphonate exposure to be associated with unusual jaw complications, particularly in patients undergoing dental procedures. This shift from general health guidance to a targeted risk profile marks a critical transition. In occupational settings—such as dental practices, oral surgery clinics, and pharmaceutical manufacturing—professionals may encounter patients or materials with histories of sustained Fosamax use. The question of exposure becomes occupationally relevant when considering how long-term medication history intersects with clinical procedures. This pivot from population-level health science to individualized exposure scenarios sets the stage for examining legal parameters, such as the statute of limitations for Fosamax-related osteonecrosis of the jaw claims in Massachusetts, where timing of diagnosis and legal action must align with state-specific deadlines.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved by the U.S. Food and Drug Administration for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition involves a disruption of blood supply to the jawbone, leading to bone death and subsequent complications such as pain, swelling, infection, and difficulty healing after dental procedures. The mechanistic pathways linking Fosamax to ONJ are complex and involve the drug's pharmacological action. Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which is beneficial for increasing bone mass in osteoporosis but can also suppress normal bone turnover in the jaw. This suppression may impair the jawbone's ability to repair microdamage and respond to local infections or trauma, such as tooth extraction. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may make it particularly susceptible to bisphosphonate-induced complications.

Risk Factors and Clinical Considerations for ONJ

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was not significantly elevated compared to placebo, possibly due to the rarity of the condition or the specific study populations.

Legal Context: Statute of Limitations for Fosamax Claims in Massachusetts

From a risk perspective, the adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling. The prescribing information includes a specific section on osteonecrosis of the jaw, detailing risk factors and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients who developed ONJ after taking Fosamax may have grounds for legal claims if they believe the warnings were insufficient or if they were not adequately informed of the risks before starting treatment. Settlement-related considerations for affected patients in Massachusetts involve the statute of limitations, which is the time limit within which a lawsuit must be filed. In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or reasonably should have been discovered. For ONJ, the timeline between exposure to Fosamax and documented harm can be variable, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability can complicate the determination of when the statute of limitations begins to run. Patients who have been diagnosed with ONJ after taking Fosamax should consult with a legal professional to assess their individual circumstances and ensure any potential claims are filed within the applicable time frame.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or reasonably should have been discovered. For ONJ, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which can affect when the clock starts. It is important to consult with a legal professional to determine the applicable deadline for your specific case.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.